Monday, October 8, 2012

Peanut Allergy "Patch" Study Now Recruiting in Chicago!

A new treatment option for peanut allergy is currently being studied in Chicago!

This treatment modality is commonly referred to as the "peanut patch", and aims to induce tolerance to peanut protein by delivering small amounts of peanut allergen to the immune system through the skin. This is similar in concept to oral and sublingual immunotherapy for foods. However, in the case of the patch, the mode of delivery is hoped to result in fewer reactions during treatment, as the allergen will not be ingested. It is certainly an interesting development, which may hold promise in the treatment of food allergy. This study is recruiting children as young as age 6 years, so it may be an option for those children who are not old enough to qualify for the Food Allergy Herbal Formula study.

Please read the memorandum below for further details:

...I would like to share with you the exciting new peanut allergy clinical trial we will be starting this fall called A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED TRIAL TO STUDY THE VIASKIN® PEANUT’S EFFICACY AND SAFETY FOR TREATING PEANUT ALLERGY IN CHILDREN AND ADULTS (VIPES STUDY). 
The VIPES study is a 12 month, multi-center trial examining Viaskin© Peanut as a potential immunotherapy treatment of peanut allergy in participants aged 6 years and older. Viaskin© Peanut is an allergen extract of peanut administered daily using the Viaskin© epicutaneous delivery system.
The goal for this study is to determine the efficacy of several doses of Viaskin© Peanut to significantly desensitize peanut allergic subjects, and to evaluate the safety of long term epicutaneous immunotherapy with Viaskin© Peanut.
You may always find the most up-to-date information about our food allergy research studies by visiting our website at You may also find a current list of all the Division of Allergy & Immunology’s clinical trials at

The Viaskin Peanut Patch